Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

SenefAS Jun. 1 at 9:07 AM

$GMAB buy now or cry later 🙃 -> -Truist assumes Genmab coverage with a Buy rating on pipeline - Highlights company's three lead assets with up to seven key readouts expected in 2026 -Sets $40 target $XBI $IBB $JNJ

0 · Reply

maikl_211 Jun. 1 at 4:24 AM

$XOM $JNJ $ASML $MA $NVDA

0 · Reply

inspector_gadget86 May. 31 at 7:02 PM

$CMPS $DJT $LLY $JNJ The push brings both opportunities and risks for patients and the companies developing the therapies.

1 · Reply

focafoca99 May. 31 at 6:40 PM

$JNJ posted Phase 3 PROTEUS results showing apalutamide plus hormone therapy reduces metastasis risk by 20% in high‑risk prostate cancer. https://www.rapidticker.com/news/jnj-johnson-johnsons-phase-3-prostate-9668ba

0 · Reply

KostasBars May. 31 at 4:27 PM

$JNJ https://news.sky.com/story/striking-cancer-jabs-destroys-tumours-in-treatment-resistant-cases-in-trial-13549483

0 · Reply

focafoca99 May. 31 at 4:10 PM

$JNJ shows strong durable responses in advanced head and neck cancer, with a 42% overall response rate and over one‑third complete responses https://www.rapidticker.com/news/jnj-rybrevant-faspro-amivantamab-and-hyaluronidase-81151d

0 · Reply

BioRich May. 31 at 3:25 PM

$SLS is an absolute disgrace this sham of a company is even mentioned in the same breath as $SMMT $RVMD $JNJ or $IBRX. If you care about the science and not the pump and dump, you'd be better suited in one of these vs. Hype stock $SLS that only tested 10 subjects for AML CR2, 10 years ago, by another company. Congrats to the real oncology companies creating real life changing treatments for the patients that so desperately deserve it. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how find these gems and learn. Let's make some (more) money. Cheers!

11 · Reply

ElliottwaveForecast May. 31 at 10:10 AM

📊 Johnson & Johnson – Elliott Wave Rally Elliott Wave analysis signals $JNJ is advancing toward the 259 level, with the bullish cycle unfolding as expected. The structure highlights continued upside momentum as long as price holds above recent pivots. 🎯 The rally toward 259 marks the next key target in the bullish sequence. Pullbacks are expected to remain supported, keeping $JNJ aligned with the upward path. Read the full analysis 👉 https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-signals-rally-toward-259/ #ElliottWave #Trading #Stocks

0 · Reply

HuhereChapter11 May. 30 at 9:36 PM

$SLS Wen $JNJ ?

0 · Reply

FarrUkk May. 30 at 5:37 PM

$JNJ Amivantamab🧐

0 · Reply

Johnson & Johnson announces Phase 3 Proteus study met primary endpoints

2026-05-31T21:40:07.000Z - 12 hours ago

Johnson & Johnson announces results from Phase 1b/2 OrigAMI-4 study

May 31, 2026, 8:39 AM EDT - 21 hours ago

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

May 31, 2026, 8:29 AM EDT - 21 hours ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

May 31, 2026, 8:27 AM EDT - 21 hours ago

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

May 31, 2026, 8:01 AM EDT - 22 hours ago

J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study

May 29, 2026, 2:00 PM EDT - 2 days ago

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

2026-05-29T12:49:22.000Z - 2 days ago

Johnson & Johnson reports new data from Phase 3 MajesTEC-9 study

May 29, 2026, 8:18 AM EDT - 2 days ago

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

May 28, 2026, 7:10 PM EDT - 3 days ago

FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage

May 28, 2026, 5:30 AM EDT - 4 days ago

J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?

May 27, 2026, 4:22 PM EDT - 4 days ago

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

May 27, 2026, 11:00 AM EDT - 4 days ago

Johnson & Johnson Transcript: Bernstein 42nd Annual Strategic Decisions Conference

May 21, 2026, 7:00 AM EDT - 10 days ago

Johnson & Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health - Abu Dhabi

May 21, 2026, 4:31 AM EDT - 11 days ago

Johnson & Johnson says nipocalimab approved in China

May 19, 2026, 11:30 AM EDT - 12 days ago

Johnson & Johnson Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 9:00 AM EDT - 12 days ago

Portal Innovations and New Brunswick Development Corporation Collaborate with Johnson & Johnson to Name the Johnson & Johnson Exchange at the New Jersey Innovation Hub in HELIX, Advancing the State's Life Sciences Leadership

May 14, 2026, 4:01 PM EDT - 17 days ago

Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation

STGW

2026-05-13T10:05:11.000Z - 18 days ago

Johnson & Johnson upgraded to Outperform from Market Perform at Leerink

May 12, 2026, 2:20 PM EDT - 19 days ago

Johnson & Johnson Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 7:45 AM EDT - 19 days ago

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

May 11, 2026, 4:34 PM EDT - 20 days ago

Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

May 11, 2026, 8:00 AM EDT - 20 days ago

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

May 7, 2026, 11:34 AM EDT - 24 days ago

This Dividend Pro Likes Banks, Semi-Equipment Stocks, Altria, and J&J

May 7, 2026, 8:00 AM EDT - 24 days ago

Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

May 5, 2026, 9:15 AM EDT - 26 days ago

CVS to drop J&J's Stelara from its main formularies

CVS

May 5, 2026, 8:05 AM EDT - 26 days ago

Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease

$Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease$

May 5, 2026, 8:05 AM EDT - 26 days ago

Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

May 5, 2026, 7:00 AM EDT - 26 days ago

Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System

May 4, 2026, 8:00 AM EDT - 27 days ago

CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

May 2, 2026, 4:00 AM EDT - 4 weeks ago

J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine

Apr 30, 2026, 8:02 AM EDT - 4 weeks ago

Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations

Apr 28, 2026, 11:10 AM EDT - 4 weeks ago

Why These 3 Forever Stocks Belong on Your Watchlist

WMT XOM

Apr 27, 2026, 4:33 PM EDT - 4 weeks ago

Johnson & Johnson to Participate in the Bernstein's 42nd Annual Strategic Decisions Conference

Apr 27, 2026, 11:03 AM EDT - 4 weeks ago

J&J sees AI halving the time to generate drug development leads

Apr 27, 2026, 8:03 AM EDT - 4 weeks ago

FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)

Apr 24, 2026, 4:30 PM EDT - 5 weeks ago

Johnson & Johnson to launch on TrumpRx with four of its prescription drugs, CBS News reports

Apr 23, 2026, 6:44 PM EDT - 5 weeks ago

Cramer says look to these 4 stocks to go with your high-flying tech names

CAH CVS UNH

Apr 23, 2026, 10:00 AM EDT - 5 weeks ago

Johnson & Johnson Transcript: AGM 2026

Apr 22, 2026, 8:05 AM EDT - 5 weeks ago

IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)

Apr 22, 2026, 4:00 AM EDT - 5 weeks ago

Johnson & Johnson Announces CE Mark Approval for the New ETHICON™ 4000 Stapler

Apr 21, 2026, 4:22 PM EDT - 5 weeks ago

Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Apr 21, 2026, 7:45 AM EDT - 5 weeks ago

Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026

Apr 17, 2026, 10:36 PM EDT - 6 weeks ago

US judge rejects Bayer bid to block Johnson & Johnson prostate cancer drug claims

Apr 17, 2026, 7:00 PM EDT - 6 weeks ago

U.S. judge rejects Bayer's bid to block Johnson & Johnson prostate cancer drug claims

Apr 15, 2026, 4:11 PM EDT - 6 weeks ago

Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference

Apr 14, 2026, 2:10 PM EDT - 6 weeks ago

Johnson & Johnson: A 20% Gain Looks Easy After Q1 Earnings Results

Apr 14, 2026, 10:51 AM EDT - 6 weeks ago

Johnson & Johnson CFO on the company's robotic surgical system

Apr 14, 2026, 10:30 AM EDT - 6 weeks ago

Tuesday's Morning Movers: ORCL & BE Extend Partnership, KMX & JNJ Earnings

ORCL BE KMX

Apr 14, 2026, 8:30 AM EDT - 6 weeks ago

Johnson & Johnson Earnings Call Transcript: Q1 2026

Apr 14, 2026, 8:30 AM EDT - 6 weeks ago

Johnson & Johnson Earnings release: Q1 2026

Apr 14, 2026, 8:30 AM EDT - 6 weeks ago

Johnson & Johnson Slides: Q1 2026

Apr 14, 2026, 8:30 AM EDT - 6 weeks ago

Johnson & Johnson Quarterly report: Q1 2026

Apr 14, 2026, 6:55 AM EDT - 6 weeks ago

J&J raises guidance for 2026 on strong start to the year

Apr 14, 2026, 6:25 AM EDT - 6 weeks ago

J&J's first-quarter profit beats estimates even as Stelara sales disappoint

Apr 14, 2026, 6:21 AM EDT - 6 weeks ago

Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%

Apr 14, 2026, 6:20 AM EDT - 6 weeks ago

Johnson & Johnson reports Q1 2026 results, raises 2026 outlook

Apr 14, 2026, 6:20 AM EDT - 6 weeks ago

J&J's First-Quarter Sales Grow on Cancer-Drug Strength

Apr 12, 2026, 2:00 PM EDT - 7 weeks ago

Goldman Sachs, Bank of America, JP Morgan, Netflix, J&J, Producer Prices, and More to Watch This Week

NFLX BAC GS JPM

Apr 10, 2026, 8:00 AM EDT - 7 weeks ago

Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision

Apr 8, 2026, 10:41 AM EDT - 7 weeks ago

Buy Johnson & Johnson Ahead of Earnings. The Stock's Run-Up Isn't Over.

Apr 7, 2026, 8:00 AM EDT - 7 weeks ago

Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe

SenefAS Jun. 1 at 9:07 AM

0 · Reply

maikl_211 Jun. 1 at 4:24 AM

$XOM $JNJ $ASML $MA $NVDA

0 · Reply

inspector_gadget86 May. 31 at 7:02 PM

$CMPS $DJT $LLY $JNJ The push brings both opportunities and risks for patients and the companies developing the therapies.

1 · Reply

focafoca99 May. 31 at 6:40 PM

0 · Reply

KostasBars May. 31 at 4:27 PM

$JNJ https://news.sky.com/story/striking-cancer-jabs-destroys-tumours-in-treatment-resistant-cases-in-trial-13549483

0 · Reply

focafoca99 May. 31 at 4:10 PM

0 · Reply

BioRich May. 31 at 3:25 PM

11 · Reply

ElliottwaveForecast May. 31 at 10:10 AM

0 · Reply

HuhereChapter11 May. 30 at 9:36 PM

$SLS Wen $JNJ ?

0 · Reply

FarrUkk May. 30 at 5:37 PM

$JNJ Amivantamab🧐

0 · Reply

betaloop May. 30 at 5:29 PM

$JNJ positive lung cancer treatment tests

0 · Reply

cubie May. 29 at 8:17 PM

$MRK $BMY $JNJ $REPL $GILD interesting and see cubie had $REPL a week ago. ur welcome if u made whopping 14,000% there today. wowee

0 · Reply

wwmeinc May. 29 at 7:45 PM

$SONA.CSE $JNJ ...Interesting tech...this Monarch system from JNJ...hmmm...stuck it here on the SONA site to keep an eye on its progress and/or potential acquisitions and/or tuck-in's...glta https://www.jnjmedtech.com/en-US/products/robotics/monarch-platform/bronchoscopy/ "It provides access to and visualization of airways, to enable healthcare providers to biopsy suspicious lung nodules. An earlier diagnosis is crucial in accelerating opportunities for treatment discussions."

0 · Reply

StocktwitsNews May. 29 at 6:54 PM

JNJ Reports Promising Survival Data From CHRYSALIS-2 Lung Cancer Study $JNJ https://stocktwits.com/news/equity/markets/jnj-survival-data-chrysalis-2-lung-cancer-study/cZgSxjPReMD

0 · Reply

Wallstfan May. 29 at 5:57 PM

$JNJ added at $225.20. Got to be in other things then just tech!

0 · Reply

GarbInvestor May. 29 at 5:44 PM

$LEGN $JNJ ceo on tv only talking about carvykti.. Something’s up.. as why wouldn’t he want to talk about own pipeline drugs, not just their new best in glass 💎

1 · Reply

jim22u May. 29 at 5:32 PM

$JNJ Why the beat down today? Sector rotation?

0 · Reply

stevemano May. 29 at 4:58 PM

$JNJ $MNKD $SNY $SPY my sister-in-law can’t wait for her little one to get Afrezza!

0 · Reply

clan May. 29 at 4:50 PM

$MNKD Congrats to kids!!! ⚠️ AFREZZA's TIME HAS ARRIVED ! ! ⚠️ FDA pediatric approval!!! $MRK $AMGN $JNJ

0 · Reply

clan May. 29 at 4:45 PM

$MNKD INHALABLE mealtime insulin! No needles for kids !!! 🚫💉 $SNY $SPY $JNJ

0 · Reply

Randomizer123 May. 29 at 3:48 PM

J&J CEO Joaquin Duato: It's our mission to become the number 1 company in oncology by 2030. Left unsaid, $JNJ needs to acquire $LEGN (Legend Biotech) to become #1 in oncology. Without ex vivo and in vivo CAR-T, these are Joaquin’s empty promises. He knows it. (Go to 2.30 min mark) https://www.cnbc.com/video/2026/05/29/jj-ceo-joaquin-duato-its-our-mission-to-become-the-number-1-company-in-oncology-by-2030.html

1 · Reply

prismmarketview May. 29 at 12:14 PM

$JNJ Johnson & Johnson scored an FDA label expansion for TREMFYA, making it the only IL‑23 inhibitor with evidence it can help stop further joint damage in active PsA while also improving symptoms. https://prismmarketview.com/fda-ruling-elevates-johnson-and-johnsons-tremfya-in-psoriatic-arthritis/

1 · Reply

Market Cap	542.42B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	21.51
Forward PE	19.94
Profit Margin	28.46%
Debt to Equity Ratio	0.46

Volume	13,901,400
Avg Vol	7,792,926
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	7%
Beta	0.27
Analysts	Strong Sell
Price Target	$260.46